853029-93-3

Usage

Uses

Used in Pharmaceutical Industry:
2-BROMO-6-METHOXY-4-PYRIDINECARBOXYLIC ACID is used as a key intermediate in the synthesis of various pharmaceuticals. Its specific molecular structure allows it to be incorporated into the development of new drugs, potentially contributing to the treatment of a range of medical conditions.
Used in Agrochemical Industry:
In the agrochemical sector, 2-BROMO-6-METHOXY-4-PYRIDINECARBOXYLIC ACID is utilized as an intermediate in the production of agrochemicals. Its role in this industry is crucial for the development of new pesticides, herbicides, and other agricultural chemicals that can enhance crop protection and yield.
Used in Organic Synthesis:
2-BROMO-6-METHOXY-4-PYRIDINECARBOXYLIC ACID is also used as a versatile building block in organic synthesis. Its pyridine ring and carboxylic acid group provide a foundation for the creation of a variety of organic compounds, expanding its applications across different chemical domains.

Upstream product

• 67-56-1 methanol 
• 2016-99-1 2,6-dibromoisonicotinic acid 
• 865-48-5 sodium t-butanolate 
• 124-41-4 sodium methylate 
• 119308-57-5 methyl 2,6-dibromoisonicotinate 
• 99-11-6 citrazinic acid 

Relevant academic research and scientific papers

Compounds and methods of use

Compounds are provided according to Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein X1, X2, X3, X4, Y, A, L1, L2, R1, R2, R5, m and n are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.

Discovery of dap-3 polymyxin analogues for the treatment of multidrug-resistant gram-negative nosocomial infections

We report novel polymyxin analogues with improved antibacterial in vitro potency against polymyxin resistant recent clinical isolates of Acinetobacter baumannii and Pseudomonas aeruginosa. In addition, a human renal cell in vitro assay (hRPTEC) was used to inform structure-toxicity relationships and further differentiate analogues. Replacement of the Dab-3 residue with a Dap-3 in combination with a relatively polar 6-oxo-1-phenyl-1,6-dihydropyridine-3- carbonyl side chain as a fatty acyl replacement yielded analogue 5x, which demonstrated an improved in vitro antimicrobial and renal cytotoxicity profiles relative to polymyxin B (PMB). However, in vivo PK/PD comparison of 5x and PMB in a murine neutropenic thigh model against P. aeruginosa strains with matched MICs showed that 5x was inferior to PMB in vivo, suggesting a lack of improved therapeutic index in spite of apparent in vitro advantages.

CO-CRYSTALS AND SALTS OF CCR3-INHIBITORS

This invention relates to co-crystals and salts of CCR3 inhibitors of formula (1), pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of diseases related with the CCR3-receptor.

Synthesis of heteroarenes using cascade radical cyclisation via iminyl radicals

Cascade radical cyclisation involving homolytic aromatic substitution has been used to synthesise new tetracycles. Treatment of vinyl iodide radical precursors with Me3Sn radicals (from hexamethylditin) yielded intermediate vinyl radicals which